Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$5.02 USD
-0.12 (-2.33%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $5.01 -0.01 (-0.20%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Foghorn Therapeutics Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
FHTX 5.02 -0.12(-2.33%)
Will FHTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FHTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FHTX
Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains?
Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should Know
FHTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing
Other News for FHTX
Is FHTX gaining bullish strength? 200 Day Moving Average Support shows up after slipping 2.33%
Is FHTX gaining bullish strength? Crossed Above 200 Day Moving Average shows up after soaring 7.08%
FHTX Fell Below 200 Day Moving Average on September 18
Foghorn Therapeutics (FHTX) Receives Buy Rating with $10 Target
Foghorn Therapeutics transferred with Buy rating at B. Riley